Life and Health Sciences Research Institute (ICVS), University of Minho, Campus of Gualtar, Braga, Portugal; ICVS/3B's - PT Government Associate Laboratory, Braga, Guimarães, Portugal.
Life and Health Sciences Research Institute (ICVS), University of Minho, Campus of Gualtar, Braga, Portugal; ICVS/3B's - PT Government Associate Laboratory, Braga, Guimarães, Portugal.
Drug Discov Today. 2022 Jan;27(1):304-314. doi: 10.1016/j.drudis.2021.07.009. Epub 2021 Jul 12.
Renal cell carcinoma (RCC) is the most common and lethal tumor of the urological system. Curative treatment of localized RCC includes nephrectomy, radio-ablation, and active surveillance, whereas metastatic RCC (mRCC) requires a combination of surgery and systemic therapy. Response to conventional therapy is limited but, recently, many novel therapies for mRCC have emerged, including targeted therapies and new immunotherapeutic agents. Nevertheless, development of resistance and limited durable responses demand new anticancer candidates with improved selectivity and efficacy. In this review, we summarize recent preclinical studies of novel natural and synthetic compounds to treat RCC, detailing their mechanisms of action and anticancer activities.
肾细胞癌（RCC）是泌尿系统中最常见和最致命的肿瘤。局限性 RCC 的治疗方法包括肾切除术、放射消融和主动监测，而转移性 RCC（mRCC）需要手术和全身治疗相结合。传统治疗的反应有限，但最近，许多新的 mRCC 治疗方法已经出现，包括靶向治疗和新的免疫治疗药物。然而，耐药性的发展和有限的持久反应需要新的抗癌候选物，以提高选择性和疗效。在这篇综述中，我们总结了最近关于治疗 RCC 的新型天然和合成化合物的临床前研究，详细介绍了它们的作用机制和抗癌活性。
